UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect

Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS assumed coverage of Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS expects investor confidence to recover and sees this positioning the sector for strong performance in 2026. Earlier on December 22, Wells Fargo initiated coverage of Arcel ...